Zymeworks to Acquire Theravance Biopharma for $929M at $17/Share, Adding COPD Drug YUPELRI

The Quick Take

• Zymeworks (ZYME) is acquiring Theravance Biopharma (TBPH) for approximately $929 million at $17 per share
• The deal adds YUPELRI (revefenacin) — the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for COPD maintenance
• A non-recourse financing structure underpins the acquisition economics
• The deal diversifies Zymeworks beyond its oncology-focused pipeline into respiratory therapeutics

Zymeworks Inc. has reached an agreement to acquire Theravance Biopharma Inc. in a deal valued at approximately $929 million, with Theravance shareholders receiving $17 per share. The strategic rationale centers on YUPELRI (revefenacin), the only approved nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease. YUPELRI's nebulizer delivery distinguishes it from inhaler-based COPD therapies, targeting a patient population with more severe disease or dexterity limitations that prevent effective inhaler use. The non-recourse financing structure — where debt is secured against the acquired asset rather than Zymeworks' broader balance sheet — preserves Zymeworks' financial flexibility post-deal.

For Zymeworks, the Theravance acquisition represents a pivot into commercially launched revenue — YUPELRI generates royalty and product revenue — diversifying away from a purely clinical-stage oncology pipeline. COPD is one of the world's largest respiratory drug markets, and a nebulized LAMA with an established prescriber base and clear mechanism differentiation offers a near-term earnings contributor. Theravance Biopharma shareholders receive a premium to recent trading at $17 per share. For biotech M&A dynamics, the deal signals continued appetite for revenue-generating specialty pharma assets where acquirers can extract commercial synergies without the development binary risk of clinical-stage deals.

Watch the regulatory close timeline and any HSR filing comments on the merger, which will determine the Q3/Q4 2026 close date. Zymeworks' next earnings call will be the first opportunity for management to quantify YUPELRI revenue contribution and cross-sell synergies with its oncology commercial infrastructure. The macro variable is the broader COPD treatment market: any label expansion for revefenacin into new patient subpopulations or payer coverage expansions in US or European markets would significantly increase YUPELRI's revenue trajectory. Competition from other nebulized respiratory agents and the pace of Zymeworks' oncology pipeline milestones are the key parallel value drivers to monitor.

Synthesized from 3 sources.